Paving the Way for Regulated FIP Treatment in Canada - 2022: Case Series Study Combining GS-441524 and Mefloquine
In 2022, Dr. Aramini designed and conducted a groundbreaking case series study in Canada, using research-quality oral medications, compounded at a pharmacy in Ontario, and overseen by a Licensed Ontario DVM. This study had the goal of making FIP treatment much more affordable, accessible, and less painful. Between November 2022 and April 2025, Dr. Aramini treated over 600 cases of FIP as part of his trial.
At the end of this session, participants will be able to:
– Recognize the significance of using “response to GS-441524” as a diagnostic test for FIP.
– Understand the importance of starting FIP treatment with GS-441524 as soon as there is a tentative diagnosis.
– Be able to apply proper and consistent dosing of GS-441524 and Mefloquine to ensure therapeutic effectiveness.
– Identify the various supportive treatments essential to ensuring the success of the FIP treatment protocol, in particular in the early phases of treatment.
Discover more from FIP Advocates and Champions
Subscribe to get the latest posts sent to your email.
